Últimas noticias sobre Amgen (NASDAQ:AMGN) Bolsa

AMGEN INC

Amgen

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Medical,Billing,Document,And,Dollar,Banknote,,Calculator,,Stathoscope.,Medical,Treatment

Health Care

Markets

AMGN

REGN

RHHBY

Trump anuncia una orden ejecutiva para reducir precios de medicamentos hasta un 80 %, aplicando la política de &#34;Nación Más Favorecida&#34;.

Trump firma orden ejecutiva histórica para reducir precios de medicamentos en EE. UU.

Eli Lilly and Co.

Equities

Government

News

ABBV

FTXH

GILD

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

Trump quiere que las farmacéuticas vuelvan a EE. UU. ¿Cómo afectarán sus aranceles a las acciones del sector?

Trump presiona a farmacéuticas con aranceles para forzar regreso a EE. UU.

Fed Chair Jerome Powell

Large Cap

Macro Economic Events

Regulations

Sector ETFs

Broad U.S. Equity ETFs

Economics

Federal Reserve

Tech

ETFs

SPDR Dow Jones Industrial Average ETF Trust

INTC

SBUX

iShares Trust Barclays 20+ Year Treasury Bond Fund

El sólido reporte laboral de marzo no calma los mercados: Nasdaq cae 20 % desde máximos, Dow entra en corrección.

Nasdaq entra en mercado bajista y el Dow en corrección pese a fuerte empleo en EE.UU.

Amgen Inc

Amgen's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NYSE">AMGN</a>) short percent of float has risen 11.34% since its last report. The company recently reported that it has 14.75 million shares sold short, which is 2.75% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.32 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Amgen Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752260424_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Amgen has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Amgen's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Amgen's peer group average for short interest as a percentage of float is 6.45%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

What Does the Market Think About Amgen?

While President Donald Trump's proposed 200% tariffs on pharmaceutical imports could potentially squeeze the profit margins, this stock is poised to &#8220;benefit&#8221; from the levies. 
What Happened: Trump announced on Tuesday that the pharma tariffs, part of a Section 232 investigation launched in April, are expected to be detailed by month's end, with a grace period of "about a year, year and a half" before implementation.
Barclays cautioned that a 200% tariff would "inflate production costs, compress profit margins, and risk supply chain disruptions.&#8221; However, the delay offers little relief, <a href="https://www.cnbc.com/2025/07/11/trump-200percent-pharma-tariffs-threaten-to-push-up-drug-prices-hit-margins.html">as</a> CNBC reported, quoting UBS analysts that it's "insufficient time" for firms to relocate manufacturing, typically a four-to-five-year process. 
But despite the potential negative impact on pharma companies, Louis Navellier told <a href="https://www.benzinga.com">Benzinga </a>that Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is &#8220;expected to benefit from tariffs on pharmaceutical imports, since the company has been boosting its domestic manufacturing.&#8221;
Additionally, Thomas Shipp, head of equity research at LPL Financial, told <a href="https://pro.benzinga.com/dashboard">Benzinga</a> that Lilly's attempt to try &#8220;to avoid PBMs,&#8221; exemplified by its direct-to-consumer model, &#8216;LillyDirect&#8217; in partnership with Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), positions it to bypass traditional pharmacy benefit managers, enhancing its resilience against tariff-related disruptions.
See Also: <a href="https://www.benzinga.com/markets/equities/25/07/46361386/bitcoin-breaches-118k-but-these-btc-mining-firms-are-still-priced-like-its-at-58k-heres-how-these-mining-stocks-could-explode">Bitcoin Breaches $118K, But These BTC Mining Firms Are Still Priced Like It&#8217;s At $58K: Here&#8217;s How These Mining Stocks Could Explode</a>
Why It Matters: Additionally, Lilly's strategic moves, including a $1.3 billion <a href="https://www.benzinga.com/m-a/25/06/45970361/eli-lilly-expands-into-gene-editing-with-verve-therapeutics-acquisition">acquisition of Verve Therapeutics</a>, signal its focus on innovation and U.S.-based growth. 
Ark Research noted that this acquisition validates gene-editing therapies for cardiovascular disease, a market with "trillions of dollars" in potential, as Lilly scales solutions like PCSK9-targeting therapies that reduce LDL-C by up to 69%.
Apart from the effects on the profitability of pharmaceutical companies, according to PhRMA, the tariffs could raise U.S. drug prices by $51 billion annually with just a 25% tariff levy, potentially increasing costs by 12.9%.
Price Action: Eli Lilly stock declined 0.078% in premarket on Friday; it was up 1.62% on a year-to-date basis but down by 15.36% over the last year.
Benzinga Edge Stock Rankings shows that LLY had a weak momentum and value ranking; however, its growth and quality metrics were very strong. The details of all the important indicators are <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">available here</a>.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="163" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge-1024x163.png" alt="" class="wp-image-981662" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge-1024x163.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge-300x48.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge-768x122.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge.png 1039w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
These are some pharma stocks and ETFs that could be impacted as Trump warned on Tuesday that long-awaited industry-wide tariffs would be announced "very soon".
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Pharma Stocks</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</td>
<td>1.62%</td>
<td>-15.36%</td>
</tr>
<tr>
<td>AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</td>
<td>8.67%</td>
<td>14.77%</td>
</tr>
<tr>
<td>Bristol-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</td>
<td>-14.56%</td>
<td>19.07%</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)</td>
<td>-21.73%</td>
<td>-48.18%</td>
</tr>
<tr>
<td>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</td>
<td>-3.12%</td>
<td>-10.05%</td>
</tr>
<tr>
<td>Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)</td>
<td>24.66%</td>
<td>63.70%</td>
</tr>
<tr>
<td>Merck &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</td>
<td>-15.28%</td>
<td>-34.85%</td>
</tr>
<tr>
<td>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</td>
<td>15.85%</td>
<td>-7.60%</td>
</tr>
<tr>
<td>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</td>
<td>9.49%</td>
<td>5.34%</td>
</tr>
</tbody>
</table>
</figure>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Pharma ETFs</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)</td>
<td>3.50%</td>
<td>-3.73%</td>
</tr>
<tr>
<td>iShares US Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td>3.15%</td>
<td>-0.88%</td>
</tr>
<tr>
<td>Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>)</td>
<td>0.68%</td>
<td>-0.49%</td>
</tr>
<tr>
<td>SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)</td>
<td>-0.16%</td>
<td>2.31%</td>
</tr>
<tr>
<td>KraneShares MSCI All China Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KURE#NYSE">KURE</a>)</td>
<td>25.74%</td>
<td>30.34%</td>
</tr>
<tr>
<td>First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>)</td>
<td>-1.00%</td>
<td>-4.29%</td>
</tr>
<tr>
<td>Direxion Daily Pharmaceutical &amp; Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PILL#NYSE">PILL</a>)</td>
<td>-14.12%</td>
<td>-14.74%</td>
</tr>
</tbody>
</table>
</figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46336115/as-trump-calls-for-3-percentage-point-rate-cut-too-late-jerome-powell-to-resign-june-fed-minutes-sh">As Trump Calls For 3-Percentage Point Rate Cut, &#8216;Too Late&#8217; Jerome Powell To Resign, June Fed Minutes Show &#8216;Uncertainty&#8217; Reigns Supreme</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Shuttertsock

AMZN

Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies

President Donald Trump is <a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46269036/scott-bessent-says-tariff-rates-set-to-boomerang-back-in-august-for-countries-faili">sticking to his Aug. 1 deadline</a> to reimpose steep tariffs, but the stock market doesn&#8217;t seem too worried. On Reddit&#8217;s <a href="https://www.reddit.com/r/stocks/comments/1luos7o/so_why_is_the_stock_market_completely_ignoring/">r/stocks</a>, one confused investor posted, &#8220;Trump just announced plans to do <a href="https://www.benzinga.com/markets/25/05/45486508/scott-bessent-signals-liberation-day-2-0-coming-if-countries-dont-sign-trade-deals-president-trump-has-put-them-on-notice">Liberation Day 2.0</a> all over again, but this time the stock market stays&#8230; up??? Does Wall Street simply not care about the economy anymore?&#8221;
<h2 class="wp-block-heading">Markets Shrug Off Tariff Threats</h2>
Wall Street dipped slightly on Tuesday, with the <a href="https://finance.yahoo.com/news/live/stock-market-today-dow-sp-500-slip-as-trump-stays-firm-on-august-tariff-deadline-announces-copper-duties-200133528.html">Dow falling</a> about 0.4% and the S&amp;P 500 slipping just 0.07%. The Nasdaq barely edged higher. These modest moves followed Trump&#8217;s declaration on <a href="https://truthsocial.com/@realDonaldTrump/posts/114818149310161097">Truth Social</a> that there would be &#8220;no extensions granted&#8221; beyond the Aug. 1 deadline, adding that countries should expect to start paying new tariffs on that day. He also announced a <a href="https://www.benzinga.com/markets/equities/25/07/46305321/copper-price-surges-trump-tariffs-stocks-july-2025">50% tariff on copper imports</a> and threatened tariffs as high as 200% on pharmaceuticals.
Don't Miss:
<ul class="wp-block-list">
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a></li>
<li>$100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.</li>
</ul>
Despite the tough talk, many investors aren't reacting the <a href="https://www.benzinga.com/25/04/44710082/trumps-liberation-day-tariffs-wipe-out-174-billion-from-the-net-worth-of-worlds-top-10-billionaires-including-warren-buffett">way they did</a> when Trump tariffs were announced on April 2, a date he referred to as &#8220;Liberation Day&#8221;.
One Reddit user boiled it down like this: &#8220;Because no one is believing the boy who cried tariff.&#8221;
That skepticism is widespread. In the Reddit thread, a term kept popping up: TACO, short for &#8220;Trump Always Chickens Out.&#8221; It&#8217;s <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/06/46180782/trumps-tariff-clock-ticks-but-taco-traders-arent-losing-their-cool">Wall Street slang</a> that reflects a belief that Trump often makes bold announcements but backs down before serious consequences hit. &#8220;It took him like an hour yesterday to start saying that the new date isn&#8217;t 100%,&#8221; another commenter noted.
Others pointed out that the market has already priced in much of the tariff risk. &#8220;When he threatened with a +50% range, the market panicked. Now the tariffs are landing in the range that the market initially anticipated,&#8221; one top commenter explained, referencing the expected 10% to 25% tariff range.
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
Even Trump's newly announced copper tariff pushed futures up more than 10%, while pharmaceutical stocks like Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) pulled back after an early rally. Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) also <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46302633/amazon-stock-slips-as-early-prime-day-sales-data-disappoints">slipped</a> about 1% as its extended Prime Day began, with some investors watching for signs that tariffs are inflating consumer prices.
Still, some think the market is underestimating the damage. &#8220;We won't really know the impact until the fall,&#8221; one Reddit investor cautioned, suggesting that companies might temporarily absorb costs before passing them on.
In short, traders may have grown numb to Trump's tariff threats. &#8220;The market believes Trump isn&#8217;t serious and will back down before any real consequences emerge,&#8221; one commenter said. Another added: &#8220;Eventually he won&#8217;t chicken out,&#8221; hinting that investor complacency could backfire if Trump follows through this time.
For now, Wall Street appears more focused on Federal Reserve policy and the upcoming Q2 earnings season.&nbsp;
As one Redditor put it, &#8220;The stock market isn&#8217;t the economy.&#8221;
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Over the last five years, the price of gold has increased by approximately 83% — Investors like Bill O&#8217;Reilly and Rudy Giuliani are using this platform to <a href="https://www.benzinga.com/money/american-hartford-gold">create customized gold IRAs to help shield their savings from inflation and economic turbulence. </a></li>
</ul>
Image: Shutterstock

An Investor Wonders Why Trump's Tariffs Aren't Shaking The Markets. 'Does Wall Street Simply Not Care About The Economy Anymore?'

A report on July 9, 2025 shows that Representative Cliff Bentz from Oregon purchase stock in Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), valued between $2,002 and $30,000. According to the July filing, the transaction occurred on June 6, 2025.
At the time of writing, Amgen shares are trading down 0.11% at $296.19.
<h3>What Representative Has Been Trading Recently</h3>
Over the previous three years, Cliff Bentz conducted 5 trades, totaling more than $254 thousand. The largest of these were in Amgen and Procter &amp; Gamble stock. Some of the most notable transactions the Rep. has executed recently include: 
<ul>
<li>Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>): $1,001 - $15,000 Purchase</li>
<li>Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>): $1,001 - $15,000 Purchase</li>
</ul>
Here's a summary of Cliff Bentz's most recent trades:
<table>
<thead>
<tr>
<th>Company</th>
<th>Ticker</th>
<th>Stock Type</th>
<th>Amount</th>
<th>Transaction Type</th>
<th>Transaction Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amgen</td>
<td>AMGN</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-06-06</td>
</tr>
<tr>
<td>Procter &amp; Gamble</td>
<td>PG</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-06-06</td>
</tr>
</tbody>
</table>
Want to keep up with Cliff Bentz and other congressional members' stock activities? Check out our <a href="https://www.benzinga.com/gov-trades/members/cliff-bentz">government trades tool</a> for real-time updates!
<h3>The Importance of Congressional Transactions</h3>
A congressional transaction is when any representative or senator either buys or sells an individual stock.
Anyone working in Congress must file a Periodic Transaction Report to inform the public of their recent transaction within 30 days of being notified of the transaction and within 45 days of the transaction date.
In April 2012, Former President Barack Obama signed the STOCK Act into law. The act prohibits members of Congress from using private information given to them by their position for personal gain such as buying or selling a stock. The act also expanded disclosure requirements for members of Congress by requiring them to file a monthly disclosure.
<h3>Why Congressional Transactions Matter</h3>
Congressional transactions shouldn't be the primary reason for an investing decision, but they can be an important factor for an investor to consider.
When a senator or representative makes a new purchase, it could be an indication they expect the stock to rise.
A sale, on the other hand, can be made for a variety of reasons, and may not necessarily mean the seller thinks the stock will go down.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Politics

General

This House of Representative Just Bought Up To $30K In Amgen Stock

As Wall Street looks ahead to the July 4 holiday weekend, a wave of optimism ripples through the trading floor, with seasoned investors poised to capitalize <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46236448/exclusive-2025s-first-half-most-searched-tickers-on-benzinga-pro-where-do-nvidia-tesla-apple-stock-rank">on emerging opportunities.</a>
<h2 class="wp-block-heading">Breaking Out: Freeport-McMoRan</h2>
On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/07/02/final-trades-amgen-caterpillar-honeywell-and-freeport-mcmoran.html">Halftime Report Final Trades</a>,&#8221; Bryn Talkington, managing partner of Requisite Capital Management, said Freeport-McMoRan Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) had resistance at $43 to $45 since 2021 and looks like it's <a href="https://www.benzinga.com/quote/FCX">breaking out above that</a>.
Supporting her view, Scotiabank analyst Orest Wowkodaw, on June 16, upgraded Freeport-McMoRan from Sector Perform to Sector Outperform and raised the price target from $43 to $48.
<h2 class="wp-block-heading">Unlocking Value: Honeywell</h2>
Kevin Simpson, founder and CIO of Capital Wealth Planning, selected Honeywell International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>), stating that the breakup value will unlock shareholder value.
On the earnings front, Honeywell will release its second-quarter financial results before the opening bell on Thursday, July 24.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<h2 class="wp-block-heading">Sales Surge: Caterpillar&#8217;s Strategy</h2>
Stephen Weiss, chief investment officer and managing partner of Short Hills Capital Partners, said Caterpillar Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) engagement with its customers is going to increase sales.
Lending support to his choice, Citigroup analyst Kyle Menges, on June 24, maintained Caterpillar with a Buy and raised the price target from $370 to $420
Joseph M. Terranova, Senior Managing Director for Virtus Investment Partners, named Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) as his final trade.
Amgen released data from the Phase 3 FORTITUDE-101 trial on June 30, detailing the first-line combination of bemarituzumab plus chemotherapy (mFOLFOX6). The study met its primary endpoint of overall survival (OS) at a pre-specified interim analysis.
Price Action:
<ul class="wp-block-list">
<li>FCX shares rose 3.9% to close at $45.77 on Wednesday.</li>
<li>Honeywell rose 0.2% to settle at $239.26 during the session.</li>
<li>Caterpillar shares gained 1.9% to settle at $398.43 on Wednesday.</li>
<li>Amgen shares rose 2.2% to close at $296.85 on Wednesday.</li>
</ul>
Check This Out: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46218519/jim-cramer-gives-utilities-stock-a-week-says-doge-not-done-clobbering-booz-allen">Jim Cramer Gives Utilities Stock &#8216;A Week,&#8217; Says DOGE &#8216;Not Done Clobbering&#8217; Booz Allen</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Media

Honeywell, Caterpillar, Freeport-McMoRan And A Health Care Stock On CNBC's 'Final Trades'

Analyst Ratings

CNBC Halftime Report Final Trades: Honeywell International, Caterpillar, Freeport-McMoran, Amgen

The <a href="https://www.benzinga.com/topic/dow-jones-industrial-average">Dow Jones Industrial Average</a> was up around 4% in the first half of 2025, with 21 of the 30 components positive year-to-date through the first six months.
The index, which contains a diverse basket of stocks across sectors, offers many dividend stocks, with some having high yields for investors.
What Happened: When looking <a href="https://www.benzinga.com/dividends">for dividend stocks</a>, the Dow Jones Industrial Average is one place with the index having a basket of what are considered blue-chip American companies.
The 30 index components have strong track records of revenue and earnings growth, and in many cases, a long history of paying dividends and raising the dividend amounts.
While investors can buy an ETF like the SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>), which tracks the entire index, another option is to buy the &#8220;Dogs of the Dow.&#8221;
The "Dogs of the Dow" is a popular strategy that often coincides with the beaten-down stocks of the index which also offer high dividend payouts.
Here are the current top-yielding dividend stocks in the Dow Jones Industrial Average after the first six months of 2025.
<ol class="wp-block-list">
<li>Verizon Communications Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>): 6.3%</li>
<li>Chevron Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>): 4.8%</li>
<li>Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>): 4.1%</li>
<li>Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>): 3.4%</li>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>): 3.4%</li>
<li>Coca-Cola Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>): 2.9%</li>
<li>UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>): 2.8%</li>
<li>Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>): 2.7%</li>
<li>Home Depot Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>): 2.5%</li>
<li>McDonald's Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>): 2.4%</li>
</ol>
In the Dow Jones Industrial Average, 28 of the 30 stocks pay out dividends. The average dividend yield of the 30 companies is 2% with the 10 highest averaging a yield of 3.5%.
Twenty of the 30 stocks in the index pay out at least a 1% dividend yield based on current stock prices.
Read Also: <a href="https://www.benzinga.com/markets/large-cap/25/07/46200141/dow-jones-2025-first-half-scoreboard-top-10-winners-losers-where-do-nvidia-apple-stock-rank">Dow Jones 2025 First Half Scoreboard: Top 10 Winners, Losers — Where Do Nvidia, Apple Stock Rank?</a>
Why It's Important: Along with stock price gains, dividends can be a nice form of consistent growth for companies and investors.
Investors can choose to collect dividend yield and put the capital to work in other stocks, or use it as income for other investments or spending. Investors can also reinvest the dividends back into the companies from which they got dividends.
Over a long period of time, dividend stocks can offer strong returns for investors with yields sometimes outpacing the returns of the overall stock market or other asset classes such as bonds and treasuries.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/best-monthly-dividend-stocks">Best Monthly Dividend Stocks</a></li>
</ul>
Photo: Shutterstock

Education

Dividends

Dogs Of The Dow: How You Can Get Dividend Stocks With Yields Up To 6.3%

Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) on Monday released data from the Phase 3 FORTITUDE-101 trial of first-line bemarituzumab plus chemotherapy (mFOLFOX6).
The study met its primary endpoint of overall survival (OS) at a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n46167179/amgen-announces-positive-topline-phase-3-results-for-bemarituzumab-in-fibroblast-growth-factor-rec" rel="noreferrer noopener">pre-specified interim analysis</a>.&nbsp;
Bemarituzumab plus chemotherapy demonstrated a&nbsp;statistically significant and clinically meaningful improvement in OS as compared to&nbsp;placebo plus chemotherapy for unresectable locally advanced or&nbsp;metastatic gastric or gastroesophageal junction (G/GEJ) cancer with FGFR2b&nbsp;overexpression and who are non-HER2 positive.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/46081494/analyst-views-mixed-as-amgens-weight-loss-diabetes-drug-maritide-shows-promise-but-has-dose-issues" rel="noreferrer noopener">Analyst Views Mixed As Amgen&#8217;s Weight Loss/Diabetes Drug MariTide Shows Promise But Has Dose Issues</a>
Gastric cancer is the fifth leading cause of cancer-related death worldwide, with nearly one million new cases and over 650,000 deaths globally each year.
The most common treatment-emergent adverse events (&gt;25%) in patients treated with bemarituzumab plus chemotherapy were reduced visual acuity, punctate keratitis, anemia, neutropenia, nausea, corneal epithelium defect, and dry eye.
While ocular events were consistent with the Phase 2 experience and observed in both arms, they occurred with greater frequency and severity in the Phase 3 bemarituzumab arm. Detailed results from the trial will be shared at a future medical meeting.
FORTITUDE-101 was conducted with the support of Zai Lab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>). Zai Lab holds co-development and commercialization rights for bemarituzumab for mainland China, Hong Kong, Macau, and Taiwan.
A Phase 3 study of bemarituzumab plus chemotherapy and nivolumab is also ongoing in patients with first-line gastric cancer, with a data readout anticipated in the second half of 2025.
Commenting on the Phase 3 results, William Blair stated, &#8220;We look forward to the detailed update to understand the survival benefit seen with bemarituzumab as well as the safety profile.&#8221;
Analyst Matt Phipps emphasized that the rates of ocular adverse events (AEs) and subsequent discontinuation of bemarituzumab will be critical data points for assessing the drug&#8217;s market potential.
He reiterated optimism for MariTide, stating, &#8220;We still see a differentiated product profile for MariTide versus currently approved GLP-1 therapies or those in late-stage development, and therefore potential for meaningful market share and a multibillion-dollar peak sales opportunity.&#8221;
Despite this, Amgen is navigating immediate challenges stemming from its established product portfolio and difficulties in expanding market share within its biosimilar franchises.
However, William Blair anticipates that upcoming clinical milestones within the next 6 to 12 months will generate significant investor enthusiasm regarding Amgen&#8217;s long-term growth trajectory. Consequently, the firm has maintained its Outperform rating for the company.
Price Action: AMGN stock is up 0.40% at $278.23 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/46036868/obesity-drugs-help-with-weight-loss-but-are-adding-fat-elsewhere" target="_blank" rel="noreferrer noopener">Obesity Drugs Help With Weight Loss But Are Adding Fat Elsewhere</a></li>
</ul>
Photo by Aunt Spray via Shutterstock

Analyst Color

Biotech

ZLAB

Amgen's Gastric Cancer Drug Improves Survival In Phase 3, Notes Ocular Side Effects

Amgen Announces Phase 3 FORTITUDE-101 Trial Of Bemarituzumab Plus Chemotherapy  Met Its Primary Endpoint

Piper Sandler analyst David Amsellem reiterates Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Overweight and maintains $328 price target.

Price Target

Reiteration

Piper Sandler Reiterates Overweight on Amgen, Maintains $328 Price Target

Across the recent three months, 8 analysts have shared their insights on Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $310.62, along with a high estimate of $330.00 and a low estimate of $280.00. This current average has increased by 0.9% from the previous average price target of $307.86. 
<img src="https://www.benzinga.com/files/images/story/2025/1750791652_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Amgen. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carter Gould</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$305.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Neutral</td>
<td>$288.00</td>
<td>-</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$328.00</td>
<td>$329.00</td>
</tr>
<tr>
<td>Salim Syed</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$280.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Trung Huynh</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$315.00</td>
<td>$319.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$320.00</td>
<td>$324.00</td>
</tr>
<tr>
<td>Colin Bristow</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$319.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$330.00</td>
<td>$328.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Amgen. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Amgen compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Amgen's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Amgen's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AMGN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Amgen analyst ratings.</a>
<h2>Get to Know Amgen Better</h2>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
<h3>Breaking Down Amgen's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Over the 3M period, Amgen showcased positive performance, achieving a revenue growth rate of 9.43% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Amgen's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 21.23% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 28.63%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Amgen's ROA stands out, surpassing industry averages. With an impressive ROA of 1.91%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 9.24, Amgen faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Amgen Stands With Analysts

Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) <a href="https://www.prnewswire.com/news-releases/results-from-amgens-phase-2-obesity-study-of-monthly-maritide-presented-at-the-american-diabetes-association-85th-scientific-sessions-302487811.html?_gl=1&#x2A;xgowcq&#x2A;_gcl_au&#x2A;MTgxMjM4ODIyNy4xNzUwMDg5NzEz&#x2A;_ga&#x2A;MTMzODE1NTQwNC4xNzM0MzgyMDk4&#x2A;_ga_MBTGG7KX5Y&#x2A;czE3NTA3ODk3NzEkbzQ2NCRnMSR0MTc1MDc5MDgyMCRqNjAkbDAkaDk5MTY2ODgwNg..">announced</a> on Monday the full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously administered <a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">monthly or less frequently</a>.
In the Phase 2 study, MariTide demonstrated up to ~20% average weight loss in people living with obesity without Type 2 diabetes (T2D) compared with 2.6% in the placebo arm and up to ~17% average weight loss in people living with obesity with T2D, compared with 1.4% in the placebo arm, per the efficacy estimand.
Weight loss had not plateaued by 52 weeks, indicating the potential for <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n46060156/results-from-amgens-phase-2-obesity-study-of-monthly-maritide-presented-at-the-american-diabetes-a" rel="noreferrer noopener">further weight reduction</a>.
In addition to meaningful weight loss, MariTide demonstrated a robust and sustained reduction in hemoglobin A1c (HbA1c) of up to 2.2%&nbsp;in obese and T2D patients.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45177521/amgens-better-than-expected-q1-earnings-take-backseat-as-eyes-are-on-maritide-obesity-data" rel="noreferrer noopener">Amgen&#8217;s Better Than Expected Q1 Earnings Take Backseat As Eyes Are On MariTide Obesity Data</a>
Weight loss with MariTide was also accompanied by improvements across pre-specified cardiometabolic measures, including waist circumference, blood pressure, high-sensitivity C-reactive protein (hs-CRP) and select lipid parameters.
No new safety signals were identified in the Phase 2 study, and tolerability was consistent with that of the GLP-1 class. The most frequently reported adverse events (AEs) were gastrointestinal (GI) related, and most were mild to moderate.
In addition to these data, complete results from the primary analysis of the Phase 1 pharmacokinetics low dose initiation (PK-LDI) study evaluating lower starting doses of MariTide were presented at the American Diabetes Association and simultaneously published in The&nbsp;New England Journal of Medicine.
The complete primary analysis showed that participants who received 21 mg/70 mg/350 mg had an overall incidence of vomiting of 24.4%, and participants who received 35 mg/70 mg/350 mg had an overall incidence of vomiting of 22.5%. There were no discontinuations due to GI AEs during the study.
Data from the Phase 2 and Phase 1 PK-LDI MariTide studies informed the Phase 3 MARITIME program.
The company recently initiated the Phase 3 MARITIME program, a 72-week chronic weight management study that will evaluate the safety, efficacy, and tolerability of&nbsp;MariTide in participants living with obesity or overweight with and without Type 2 diabetes.
Participants will be randomized to one of three target doses, each with an initial starting dose of 21 mg, followed by 35 mg and then 70 mg, over a further optimized eight-week dose escalation period. 
Amgen also expects to initiate Phase 3 clinical outcomes studies for atherosclerotic cardiovascular disease and heart failure and a Phase 3 study for obstructive sleep apnea in 2025. 
William Blair writes, &#8220;Treatment policy estimand weight loss data clearly disappointing (12.3% to 16.2% weight loss range), but we believe reducing discontinuations with additional titration and longer time point (72 weeks) could still put Phase 3 results near 20%.&#8221;
Analyst Matt Phipps says the Phase 2 results show lower doses can still lead to meaningful weight loss. The 280 mg dose led to the quickest results. However, he questions if higher doses might be better for less frequent dosing, such as every two or three months.
The analyst questions whether expanding the dosing interval beyond every four weeks (Q4W) would result in increased GI adverse events on subsequent doses or a loss of tolerance.
Price Action: AMGN stock is up 1.96% at $277.78 at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46021366/mark-cuban-corrects-elizabeth-warren-as-she-slams-jnj-pfe-for-higher-prices-and-zero-taxes-on-big-pharma-pbms-corrupt-healthcare" target="_blank" rel="noreferrer noopener">Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: &#8216;PBMs Corrupt Healthcare&#8217;</a></li>
</ul>
Photo: Courtesy of Amegen

Analyst Views Mixed As Amgen's Weight Loss/Diabetes Drug MariTide Shows Promise But Has Dose Issues

Cantor Fitzgerald analyst Carter Gould reiterates Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Neutral and maintains $305 price target.

Cantor Fitzgerald Reiterates Neutral on Amgen, Maintains $305 Price Target

Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) shares are trading lower by 5.7% to $272.88 Monday afternoon after the company released full results from part one of its phase two study of MariTide, its investigational obesity treatment.
What To Know: The therapy, a long-acting, peptide-antibody conjugate administered monthly or less frequently, showed promising <a href="https://www.benzinga.com/pressreleases/25/06/n46060156/results-from-amgens-phase-2-obesity-study-of-monthly-maritide-presented-at-the-american-diabetes-a">weight loss benefits</a> but failed to boost investor confidence.
In the phase two trial, MariTide showed up to 20% average weight loss in people with obesity without Type 2 diabetes and up to 17% in those with the condition, significantly outperforming placebo.
Additionally, MariTide <a href="https://www.benzinga.com/pressreleases/25/06/n46060156/results-from-amgens-phase-2-obesity-study-of-monthly-maritide-presented-at-the-american-diabetes-a">delivered</a> notable reductions in hemoglobin A1c (up to 2.2%) and improvements in several cardiometabolic measures. Importantly, weight loss did not plateau by 52 weeks.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46060610/fractyl-health-stock-is-trading-lower-monday-whats-going-on">Fractyl Health Stock Is Trading Lower Monday: What&#8217;s Going On?</a>
Safety data showed gastrointestinal side effects, mostly mild to moderate, with improved tolerability during dose escalation. The findings also included data from the phase one PK-LDI study, which assessed dosing strategies and showed low discontinuation rates.
Despite the strong clinical results, the market reaction was negative, possibly due to concerns about competitive pressures in the GLP-1 space or the long road ahead for phase three trials.
Amgen launched its MARITIME Phase 3 program and plans additional studies targeting cardiovascular disease, heart failure and sleep apnea. An investor webcast is scheduled Monday evening.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, AMGN has a 52-week high of $346.85 and a 52-week low of $253.30.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46059932/kratos-defense-stock-is-rising-monday-whats-going-on-2">Kratos Defense Stock Is Rising Monday: What&#8217;s Going On?</a>
<h1 class="wp-block-heading">How To Buy AMGN Stock</h1>
Besides going to a brokerage platform to purchase a share — or fractional share — of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, Amgen is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46059497/stocks-rise-oil-tumbles-despite-irans-strikes-on-us-bases-whats-driving-markets-monday">Stocks Rise, Oil Tumbles Despite Iran&#8217;s Strikes On US Bases: What&#8217;s Driving Markets Monday?</a></li>
</ul>
Image: Courtesy of Amgen

Movers

Amgen (AMGN) Stock Falls After Mixed MariTide Trial Update

WIIM

Amgen shares are trading lower after the company announced full results from Part 1 of the Phase 2 study of MariTide.

MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau, and Delivered Significant Cardiometabolic Improvements at 52 Weeks
In People Living With Obesity With Type 2 Diabetes, MariTide Demonstrated Up to ~17% Average Weight Loss and Robust HbA1c Improvements
Dose Escalation With Lower Starting Doses Substantially Improved Gastrointestinal Tolerability, Without Compromising Efficacy
The MARITIME Phase 3 Chronic Weight Management Studies are Actively Enrolling, and Phase 3 Studies in People Living With Atherosclerotic Cardiovascular Disease, Heart Failure and Obstructive Sleep Apnea Will be Initiated in 2025

Amgen Says MariTide, First Monthly Or Less Frequently Dosed Obesity Treatment, Showed Up To ~20% Average Weight Loss Without Weight Loss Plateau, And Delivered Cardiometabolic Improvements At 52 Weeks

MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau, and Delivered Significant Cardiometabolic Improvements at 52 Weeks
In People Living With Obesity With Type 2 Diabetes, MariTide Demonstrated Up to ~17% Average Weight Loss and Robust HbA1c Improvements
Dose Escalation With Lower Starting Doses Substantially Improved Gastrointestinal Tolerability, Without Compromising Efficacy
The MARITIME Phase 3 Chronic Weight Management Studies are Actively Enrolling, and Phase 3 Studies in People Living With Atherosclerotic Cardiovascular Disease, Heart Failure and Obstructive Sleep Apnea Will be Initiated in 2025
THOUSAND OAKS, Calif., June 23, 2025 /PRNewswire/ -- Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) today announced full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously administered monthly or less frequently. In addition to these data, complete results from the primary analysis of the Phase 1 pharmacokinetics low dose initiation (PK-LDI) study evaluating lower starting doses of MariTide were presented as part of an expert-led Symposium at the 85th American Diabetes Association (ADA) 85th Scientific Sessions and simultaneously <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4454195-1&amp;h=1438875105&amp;u=https%3A%2F%2Fwww.nejm.org%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2504214&amp;a=published">published</a>&nbsp;in The&nbsp;New England Journal of Medicine.
In the Phase 2 study, MariTide demonstrated up to ~20% average weight loss in people living with obesity without Type 2 diabetes (T2D) compared with 2.6% in the placebo arm, and up to ~17% average weight loss in people living with obesity with T2D, compared with 1.4% in the placebo arm, per the efficacy estimand.1 Weight loss had not plateaued by 52 weeks, indicating the potential for further weight reduction. In addition to meaningful weight loss, MariTide demonstrated a robust and sustained reduction in hemoglobin A1c (HbA1c) of up to 2.2%1&nbsp;in people living with obesity and T2D. Weight loss with MariTide was also accompanied by improvements across pre-specified cardiometabolic measures, including waist circumference, blood pressure, high-sensitivity C-reactive protein (hs-CRP) and select lipid parameters.
No new safety signals were identified in the Phase 2 study and tolerability was consistent with the GLP-1 class. The most frequently reported adverse events (AEs) were gastrointestinal (GI) related, and most were mild to moderate. The study employed a rigorous daily patient reporting tool known as the MINVR (modified index of nausea/vomiting/retching) to actively solicit the presence of select GI symptoms in addition to standard unsolicited AE reporting. Gastrointestinal events were predominantly limited to initial dosing and less frequent when dose escalation was used without compromising efficacy. Discontinuation rates of MariTide due to GI AEs in the dose escalation arms (up to 7.8%) were lower than non-dose escalation arms.
The Phase 1 PK-LDI study assessed PK and also used the MINVR reporting tool to assess different dose escalation schedules of MariTide. The complete primary analysis showed participants that received 21 mg/70 mg/350 mg had an overall incidence of vomiting of 24.4% and participants that received 35 mg/70 mg/350 mg had an overall incidence of vomiting of 22.5%. There were no discontinuations due to GI AEs at any time during the study.
Data from the Phase 2 and Phase 1 PK-LDI MariTide studies informed the Phase 3 MARITIME program. The recently initiated Phase 3, 72-week chronic weight management studies will evaluate the safety, efficacy and tolerability of&nbsp;MariTide in participants living with obesity or overweight with and without Type 2 diabetes. Participants will be randomized to one of three target doses, each with an initial starting dose of 21 mg, followed by 35 mg and then 70 mg, over a further optimized eight-week dose escalation period. Amgen also expects to initiate Phase 3 clinical outcomes studies for atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF), as well as a Phase 3 study for obstructive sleep apnea (OSA) in 2025.&nbsp;

Amgen Announces Full Results From Part 1 Of Phase 2 Study Of MariTide; Presents Complete Results From Primary Analysis Of Phase 1 PK-LDI Study Evaluating Lower Starting Doses Of MariTide At ADA 85th Scientific Sessions

A heated debate over the U.S. healthcare system erupted on X, pitting billionaire entrepreneur Mark Cuban against Sen. Elizabeth Warren (D-Mass) over the root causes of soaring drug prices.
What Happened: The clash, unfolding as of Friday, has reignited discussions on Pharmacy Benefit Managers (PBMs) and Big Pharma's tax practices, with the Senate poised to address reform amid rising public scrutiny.
Enter Cuban, the Dallas Mavericks owner and founder of Cost Plus Drugs, who fired back with a pointed correction.
In a post quoting Warren, Cuban argued that PBMs—not Big Pharma—are the true culprits behind inflated drug prices.
&#8220;PBMs corrupt healthcare,&#8221; he wrote, explaining that these intermediaries control formularies and manipulate prices to maximize rebate revenue, with <a href="https://www.benzinga.com/25/05/45487788/trumps-drug-price-order-hits-pbms-hardest-cvs-cigna-unh-in-focus-as-experts-highlight-racket-and-pricing-distortion">three major PBMs</a> negotiating over 90% of rebates for commercial insurance plans. 
Warren, in her post, had blamed pharmaceutical giants like Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) and Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) for charging Americans the &#8220;highest drug prices in the world&#8221; while paying &#8220;zero dollars in federal taxes.&#8221;
Citing data from her Senate Finance Committee role, Warren highlighted how these companies, alongside AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), and Merck &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), have exploited tax loopholes from the 2017 Tax Cuts and Jobs Act to shield billions in profits.
&#8220;Republicans want to make it worse. I&#8217;m fighting back,&#8221; she declared, sharing <a href="https://www.cnbc.com/2025/06/17/pfizer-merck-jj-others-face-scrutiny-over-tax-loophole-extension.html">a</a> CNBC headline and urging action against what she calls a &#8220;rigged tax system.&#8221; 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">No. It&#39;s because PBMs corrupt healthcare. Big Pharma wishes they could set their own pricing. They don&#39;t. PBMs control formularies and manipulate prices, in exchange for providing pharma access to patients. It&#39;s how they maximize rebate revenue. In fact, 3 PBMs NEGOTIATE… <a href="https://t.co/GpN4mnzvOM">https://t.co/GpN4mnzvOM</a>
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1935705831930298562?ref_src=twsrc%5Etfw">June 19, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also:&nbsp;<a href="https://www.benzinga.com/etfs/sector-etfs/25/06/46013679/dan-ives-says-market-is-massively-underestimating-this-ai-play-urges-investors-to-look-beyong-mag-7">Dan Ives Says Market Is ‘Massively Underestimating' This AI Play, Urges Investors To Look Beyond Mag 7</a>
Why It Matters: Cuban has been a c<a href="https://www.benzinga.com/personal-finance/25/04/44674382/mark-cuban-says-big-insurance-companies-and-pbms-control-healthcare-costs-everyone-has-to-kiss-their-a-and-accept-the-complications">ritic of the healthcare system</a>, saying that it should be simple. According to him, it&#8217;s become overly complicated by big insurance companies and PBMs.
These groups, he says, act as middlemen, controlling not just the costs but also the accessibility of care.
He blames PBMs for lack of transparency, inflated specialty drug prices, rebate distortion, formulary restrictions, and &#8220;Sh–ing on&#8221; on independent pharmacies.
Some significant firms engaged in the PBM business listed in the U.S. include;
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Stocks</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</td>
<td>51.15%</td>
<td>9.57%</td>
</tr>
<tr>
<td>Cigna Group. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>)</td>
<td>14.54%</td>
<td>-6.95%</td>
</tr>
<tr>
<td>UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</td>
<td>-39.11%</td>
<td>-36.60%</td>
</tr>
</tbody>
</table>
</figure>
Meanwhile, here is how some pharmaceutical sector ETFs have performed;
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Pharma ETFs</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)</td>
<td>1.69%</td>
<td>-4.48%</td>
</tr>
<tr>
<td>iShares US Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td>-0.49%</td>
<td>-1.85%</td>
</tr>
<tr>
<td>Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>)</td>
<td>-3.23%</td>
<td>-1.64%</td>
</tr>
<tr>
<td>SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)</td>
<td>-4.06%</td>
<td>2.61%</td>
</tr>
<tr>
<td>KraneShares MSCI All China Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KURE#NYSE">KURE</a>)</td>
<td>20.55%</td>
<td>22.94%</td>
</tr>
<tr>
<td>First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>)</td>
<td>-5.44%</td>
<td>-6.27%</td>
</tr>
<tr>
<td>Direxion Daily Pharmaceutical &amp; Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PILL#NYSE">PILL</a>)</td>
<td>-23.49%</td>
<td>-14.63%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were mixed in premarket on Friday. The SPY was down 0.30% at $595.67, while the QQQ was 0.015% higher at $529.07, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46016347/this-stock-just-popped-30-in-5-days-now-expert-says-it-looks-potentially-explosive">This Stock Just Popped 30% In 5 Days — Now Expert Says It ‘Looks Potentially Explosive'</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Insurance

Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'

Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) revealed 14 unusual trades.
Delving into the details, we found 35% of traders were bullish, while 57% showed bearish tendencies. Out of all the trades we spotted, 11 were puts, with a value of $691,707, and 3 were calls, valued at $114,240.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $285.0 to $330.0 for Amgen during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Amgen stands at 509.0, with a total volume reaching 1,427.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Amgen, situated within the strike price corridor from $285.0 to $330.0, throughout the last 30 days.
<h3>Amgen 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750266051_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$24.75</td>
<td>$23.9</td>
<td>$23.9</td>
<td>$290.00</td>
<td>$210.3K</td>
<td>328</td>
<td align="right">88</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$26.65</td>
<td>$26.35</td>
<td>$26.65</td>
<td>$295.00</td>
<td>$118.9K</td>
<td>18</td>
<td align="right">45</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$22.75</td>
<td>$21.55</td>
<td>$21.6</td>
<td>$285.00</td>
<td>$105.9K</td>
<td>90</td>
<td align="right">49</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$12.65</td>
<td>$10.7</td>
<td>$10.72</td>
<td>$330.00</td>
<td>$57.8K</td>
<td>1.0K</td>
<td align="right">54</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$16.85</td>
<td>$16.55</td>
<td>$16.85</td>
<td>$290.00</td>
<td>$45.4K</td>
<td>453</td>
<td align="right">36</td>
</tr>
</tbody>
</table>

<h3>About Amgen</h3>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
In light of the recent options history for Amgen, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Amgen's Current Market Status</h3>
<ul>
<li>Trading volume stands at 743,161, with AMGN's price up by 0.11%, positioned at $290.37.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 48 days.</li>
</ul>
<h3>Professional Analyst Ratings for Amgen</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $288.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Guggenheim downgraded its action to Neutral with a price target of $288. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Amgen options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Amgen Options Trading: A Deep Dive into Market Sentiment

High-rolling investors have positioned themselves bearish on Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in AMGN often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 13 options trades for Amgen. This is not a typical pattern.
The sentiment among these major traders is split, with 30% bullish and 61% bearish. Among all the options we identified, there was one put, amounting to $38,319, and 12 calls, totaling $751,466.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $250.0 to $295.0 for Amgen over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Amgen options trades today is 973.0 with a total volume of 2,963.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Amgen's big money trades within a strike price range of $250.0 to $295.0 over the last 30 days.
<h3>Amgen 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749495681_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$15.1</td>
<td>$13.45</td>
<td>$13.45</td>
<td>$280.00</td>
<td>$225.9K</td>
<td>1.7K</td>
<td align="right">672</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$13.05</td>
<td>$12.85</td>
<td>$13.05</td>
<td>$280.00</td>
<td>$58.7K</td>
<td>1.7K</td>
<td align="right">179</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$14.75</td>
<td>$13.2</td>
<td>$13.2</td>
<td>$280.00</td>
<td>$56.7K</td>
<td>1.7K</td>
<td align="right">328</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$14.4</td>
<td>$13.15</td>
<td>$13.15</td>
<td>$280.00</td>
<td>$55.2K</td>
<td>1.7K</td>
<td align="right">132</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$13.15</td>
<td>$12.85</td>
<td>$13.15</td>
<td>$280.00</td>
<td>$53.9K</td>
<td>1.7K</td>
<td align="right">90</td>
</tr>
</tbody>
</table>

<h3>About Amgen</h3>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Having examined the options trading patterns of Amgen, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Amgen</h3>
<ul>
<li>With a trading volume of 951,644, the price of AMGN is up by 0.32%, reaching $291.26.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 57 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Amgen</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $308.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Guggenheim lowers its rating to Neutral with a new price target of $288. 
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for Amgen, targeting a price of $328. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Amgen, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Unpacking the Latest Options Trading Trends in Amgen

Opinion

Press Releases

BetterInvesting™ Magazine Update on Stride Inc. (NYSE: LRN) and Amgen Inc. (NASDAQ: AMGN)

AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE

IMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTS

BetterInvesting™ Magazine Update on The Walt Disney Co. (NYSE: DIS)

AMGEN TO PRESENT AT GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

Entertainment

AMGEN AND FOOTBALL LEGEND BARRY SANDERS HIGHLIGHT DANGERS OF BAD CHOLESTEROL IN NEW DOCUMENTARY

AMGEN'S PHASE 2 MARITIDE DATA TO BE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS

RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

BioMarin Pharmaceutical

BioNTech

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Caris Life Sciences

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Insmed

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeOne Medicines Ltd. - American Depositary Shares

BeOne Medicines

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Comments

Amgen

Noticias

Últimas noticias sobre Amgen (NASDAQ:AMGN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL